Hilar cholangiocarcinoma
MONDO:0003345A cholangiocarcinoma that arises from the junction, or adjacent to the junction, of the right and left hepatic ducts.
Also known as: Klatskin tumor, Klatskin's tumor, cholangiocarcinoma of hilar portion of hepatic duct, hilar CC, hilar CCA, hilar cholangiocarcinoma, hilar portion of hepatic duct cholangiocarcinoma, hilar cholangiocellular carcinoma
2993 clinical trials for this condition and its sub-types, 36 tagged with Hilar cholangiocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New combo attack on biliary cancers: targeted drug plus chemo shows promise
Disease control OngoingThis study tests whether adding the targeted drug binimetinib to standard chemotherapy (mFOLFOX6) can shrink tumors or extend survival in people with advanced biliary tract cancers that have certain genetic changes (MAPK pathway alterations). About 66 participants whose cancer wo…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug aims to stop bile duct cancer from returning after surgery
Disease control OngoingThis global phase 3 trial is testing whether adding the immunotherapy drug rilvegostomig to standard chemotherapy can help prevent biliary tract cancer from coming back after surgery. About 757 people who had their cancer completely removed will receive either rilvegostomig or a …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug targets bile duct cancer in small trial
Disease control OngoingThis phase II trial tests a drug called sacituzumab govitecan in 15 people with advanced bile duct cancer that has spread or returned after treatment. The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a toxic payload to kill them. Researchers…
Phase 2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC